Over the past two decades, interest in hypofractionated radiotherapy for prostate cancer has intensified. Research has indicated that prostate cancer cells may have a lower alpha/beta ratio than once supposed, and hypofractionation could widen the therapeutic window. These suppositions have largely been borne out in large, randomized studies of moderately hypofractionated treatment. More recently, ultra-hypofractionation using stereotactic body radiotherapy (SBRT) has been adopted as an acceptable alternative to moderately hypofractionated or conventional regimens with a growing body of literature demonstrating excellent oncologic outcomes with a comparable side effect profile. In this chapter, the practical aspects of implementing a prostate SBRT program are described, with a focus on appropriate selection of patients, treatment planning and delivery, symptom management, patient follow-up, and expected outcomes.